ARTICLE | Clinical News
Bendeka bendamustine regulatory update
December 21, 2015 8:00 AM UTC
FDA approved an NDA from Eagle for Bendeka bendamustine to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of tr...